DeepMed Research

AGENUS INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Conditions: Colorectal Cancer (CRC)
Pancreatic Cancer
Non-Small Cell Lung Cancer (NSCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Sarcoma
Ovarian Cancer
Prostate Cancer

First Posted Date: 2024-12-30

Last Posted Date: 2024-12-30

Lead Sponsor: Agenus Inc.

Registration Number: NCT06751524

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Botensilimab
Drug: Gemcitabine
Drug: Nab-paclitaxel

First Posted Date: 2022-11-29

Last Posted Date: 2025-02-17

Lead Sponsor: Agenus Inc.

Target Recruit Count: 81

Registration Number: NCT05630183

Locations: 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
USC Norris Oncology, Newport Beach, California, United States

and more 32 locations

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Botensilimab
Drug: Standard of Care
Drug: Balstilimab

First Posted Date: 2022-11-08

Last Posted Date: 2025-05-14

Lead Sponsor: Agenus Inc.

Target Recruit Count: 234

Registration Number: NCT05608044

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇷🇺
Branch office of " Hadassah Medical Ltd", Moscow, Russian Federation

and more 62 locations

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Conditions: Cancer

First Posted Date: 2022-10-10

Last Posted Date: 2025-04-30

Lead Sponsor: Agenus Inc.

Registration Number: NCT05572970

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸
Hoag Gynecologic Oncology, Newport Beach, California, United States

and more 4 locations

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Phase 2

Active, not recruiting

Conditions: Advanced Melanoma

Interventions: Drug: Botensilimab
Drug: Balstilimab

First Posted Date: 2022-09-07

Last Posted Date: 2025-03-10

Lead Sponsor: Agenus Inc.

Target Recruit Count: 174

Registration Number: NCT05529316

Locations: 🇧🇪
Universitair Ziekenhuis Brussel, Jette, Belgium
🇧🇷
Oncosite - Centro de Pesquisa Clinica Em Oncologia, Ijuí, Brazil
🇧🇷
Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho, Jaú, Brazil

and more 48 locations

Study of AGEN1571 in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: AGEN1571
Drug: Balstilimab
Drug: Botensilimab

First Posted Date: 2022-05-17

Last Posted Date: 2025-04-30

Lead Sponsor: Agenus Inc.

Target Recruit Count: 22

Registration Number: NCT05377528

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

and more 3 locations

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Phase 2

Withdrawn

Conditions: Cervical Cancer

Interventions: Drug: Balstilimab + Zalifrelimab
Drug: Balstilimab

First Posted Date: 2021-09-02

Last Posted Date: 2024-03-28

Lead Sponsor: Agenus Inc.

Registration Number: NCT05033132

Locations: 🇨🇳
Betta Clinical Study Site 27, Wuhu, Anhui, China
🇨🇳
Betta Clinical Study Site 10, Zhanjiang, Guangdong, China
🇨🇳
Betta Clinical Study Site 43, Wuhan, Hubei, China

and more 40 locations

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase 3

Withdrawn

Conditions: Metastatic Cervical Cancer
Advanced Cancer

Interventions: Drug: Balstilimab (BAL)
Drug: Topotecan
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Irinotecan
Drug: Pemetrexed

First Posted Date: 2021-06-29

Last Posted Date: 2022-10-05

Lead Sponsor: Agenus Inc.

Registration Number: NCT04943627

Locations: 🇦🇲
Hematology Center after prof. R. Yeolyan, Yerevan, Armenia
🇦🇲
National Center of Oncology named after V.A. Fanarjian, Yerevan, Armenia
🇺🇸
Optimum Research (Southwest Women's Oncology Center), Albuquerque, New Mexico, United States

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Phase 2

Withdrawn

Conditions: Angiosarcoma

Interventions: Drug: AGEN2034
Drug: AGEN1884

First Posted Date: 2020-10-29

Last Posted Date: 2022-01-11

Lead Sponsor: Agenus Inc.

Registration Number: NCT04607200

A Study in Subjects With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumor

Interventions: Drug: AGEN1223
Drug: AGEN1223 and balstilimab

First Posted Date: 2019-11-07

Last Posted Date: 2022-03-03

Lead Sponsor: Agenus Inc.

Target Recruit Count: 19

Registration Number: NCT04156100

Locations: 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
University of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy